This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

OCUL Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.50%

Insider Buying (Last 12 Months): $6,999,999.52

Insider Selling (Last 12 Months): $224,666.50

Ocular Therapeutix Insider Trading History Chart

Ocular Therapeutix Share Price & Price History

^$8.83

▲ +0.31 (3.64%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

[Urgent] Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Ocular Therapeutix Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/23/2024	Sanjay Nayak	Insider	Sell	1,832	$9.02	$16,524.64	176,194
5/23/2024	Sanjay Nayak	Insider	Sell	2,274	$5.84	$13,280.16	178,026
2/26/2024	Summer Road Llc	Major Shareholder	Buy	930,851	$7.52	$6,999,999.52	8,591,401
1/31/2024	Antony C. Mattessich	CEO	Sell	18,338	$4.95	$90,773.10	427,943
1/31/2024	Donald Notman	CFO	Sell	6,433	$4.95	$31,843.35	139,932
1/31/2024	Philip C Strassburger	General Counsel	Sell	6,831	$4.95	$33,813.45	109,218
1/31/2024	Rabia Gurses Ozden	Insider	Sell	7,764	$4.95	$38,431.80	92,767
8/30/2023	Antony C. Mattessich	CEO	Buy	6,500	$3.81	$24,765.00	6,500
7/7/2023	Rabia Gurses Ozden	Insider	Sell	832	$4.93	$4,101.76	100,531
2/6/2023	Antony C. Mattessich	CEO	Sell	19,669	$4.24	$83,396.56	446,281
2/6/2023	Christopher G White	Insider	Sell	5,829	$4.24	$24,714.96	94,766
2/6/2023	Donald Notman	CFO	Sell	6,476	$4.24	$27,458.24	139,387
2/6/2023	Philip C Strassburger	General Counsel	Sell	6,181	$4.24	$26,207.44	109,071
11/7/2022	Summer Road Llc	Major Shareholder	Buy	7,328	$3.50	$25,648.00	6,122,089
10/10/2022	Summer Road Llc	Major Shareholder	Buy	10,000	$4.00	$40,000.00	6,104,761
9/29/2022	Summer Road Llc	Major Shareholder	Buy	18,800	$4.04	$75,952.00	6,094,761
9/27/2022	Summer Road Llc	Major Shareholder	Buy	130,000	$4.68	$608,400.00	6,074,761
2/23/2022	Summer Road Llc	Major Shareholder	Buy	10,000	$4.80	$48,000.00
2/18/2022	Summer Road Llc	Major Shareholder	Buy	40,000	$5.00	$200,000.00
1/27/2022	Summer Road Llc	Major Shareholder	Buy	1,477	$5.20	$7,680.40
1/24/2022	Summer Road Llc	Major Shareholder	Buy	44,400	$5.31	$235,764.00
1/20/2022	Summer Road Llc	Major Shareholder	Buy	17,948	$5.70	$102,303.60
1/18/2022	Summer Road Llc	Major Shareholder	Buy	6,807	$6.00	$40,842.00
1/13/2022	Summer Road Llc	Major Shareholder	Buy	10,000	$6.20	$62,000.00
12/15/2021	Summer Road Llc	Major Shareholder	Buy	15,000	$6.22	$93,300.00
12/13/2021	Summer Road Llc	Major Shareholder	Buy	10,510	$6.50	$68,315.00
12/10/2021	Summer Road Llc	Major Shareholder	Buy	30,000	$6.65	$199,500.00
12/8/2021	Summer Road Llc	Major Shareholder	Buy	5,300	$6.75	$35,775.00
12/6/2021	Summer Road Llc	Major Shareholder	Buy	55,600	$6.13	$340,828.00

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

SEC Filings (Institutional Ownership Changes) for Ocular Therapeutix (NASDAQ:OCUL)

59.21% of Ocular Therapeutix stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Ocular Therapeutix Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	3,271,207	$28.46M	0.0%	-5.2%	2.098%
11/15/2024	Barclays PLC	511,522	$4.45M	0.0%	+37.1%	0.325%
11/15/2024	Wellington Management Group LLP	462,864	$4.03M	0.0%	+47.1%	0.297%
11/15/2024	State Street Corp	3,476,292	$30.24M	0.0%	-11.3%	2.230%
11/15/2024	Point72 Asset Management L.P.	2,040,620	$17.75M	0.0%	-24.6%	1.309%
11/15/2024	Polar Asset Management Partners Inc.	492,900	$4.29M	0.1%	N/A	0.316%
11/15/2024	Patient Square Capital LP	235,498	$2.05M	0.8%	N/A	0.151%
11/15/2024	HighVista Strategies LLC	65,027	$0.57M	0.2%	+5.1%	0.042%
11/15/2024	Erste Asset Management GmbH	235,800	$2.05M	0.0%	N/A	0.151%
11/14/2024	PFM Health Sciences LP	402,843	$3.51M	0.2%	N/A	0.258%
11/14/2024	Braidwell LP	2,239,770	$19.49M	0.6%	+36.3%	1.436%
11/14/2024	Knoll Capital Management LLC	600,400	$5.22M	2.6%	+199.6%	0.385%
11/14/2024	Verition Fund Management LLC	62,501	$0.54M	0.0%	N/A	0.040%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	147,684	$1.29M	0.0%	-20.6%	0.095%
11/14/2024	Acuta Capital Partners LLC	1,190,071	$10.35M	8.4%	-57.1%	0.763%
11/13/2024	BNP Paribas Financial Markets	35,801	$0.31M	0.0%	-35.3%	0.023%
11/13/2024	FMR LLC	434,369	$3.78M	0.0%	+7,098.7%	0.279%
11/13/2024	The Manufacturers Life Insurance Company	130,202	$1.13M	0.0%	+11.3%	0.084%
11/12/2024	Charles Schwab Investment Management Inc.	1,110,460	$9.66M	0.0%	+146.6%	0.712%
11/12/2024	Banco Santander S.A.	172,231	$1.50M	0.0%	-54.4%	0.110%
11/9/2024	Intech Investment Management LLC	48,483	$0.42M	0.0%	N/A	0.031%
11/5/2024	GSA Capital Partners LLP	126,681	$1.10M	0.1%	N/A	0.081%
11/1/2024	Capital Performance Advisors LLP	8,034	$70K	0.0%	N/A	0.005%
10/31/2024	Principal Financial Group Inc.	14,561	$0.13M	0.0%	-44.8%	0.009%
10/30/2024	Rosalind Advisors Inc.	885,000	$7.70M	4.8%	+18.0%	0.568%
10/25/2024	Deltec Asset Management LLC	2,600,073	$22.62M	4.5%	+0.4%	1.668%
10/25/2024	China Universal Asset Management Co. Ltd.	29,989	$0.26M	0.0%	+64.8%	0.019%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	5,639	$49K	0.0%	+22.0%	0.004%
10/23/2024	Assenagon Asset Management S.A.	2,825,756	$24.58M	0.0%	N/A	1.812%
10/16/2024	Nottingham Advisors Inc.	185,766	$1.62M	0.2%	-3.9%	0.120%
10/11/2024	Creative Planning	20,947	$0.18M	0.0%	N/A	0.013%
10/10/2024	Essex Investment Management Co. LLC	443,677	$3.86M	0.7%	+0.3%	0.286%
10/7/2024	Diversified Trust Co	12,239	$0.11M	0.0%	N/A	0.008%
10/3/2024	SG Americas Securities LLC	45,187	$0.39M	0.0%	N/A	0.029%
8/22/2024	Cetera Investment Advisers	739,044	$5.06M	0.0%	+1.8%	0.477%
8/20/2024	Nantahala Capital Management LLC	1,000,000	$6.84M	0.4%	N/A	0.646%
8/19/2024	Point72 Asset Management L.P.	2,706,663	$18.51M	0.0%	N/A	1.736%
8/16/2024	Second Line Capital LLC	262,810	$1.80M	0.6%	N/A	0.170%
8/16/2024	Algert Global LLC	10,114	$69K	0.0%	N/A	0.007%
8/15/2024	The Manufacturers Life Insurance Company	116,964	$0.80M	0.0%	+61.5%	0.076%
8/15/2024	Dark Forest Capital Management LP	12,383	$85K	0.0%	-39.3%	0.008%
8/14/2024	Squarepoint Ops LLC	64,911	$0.44M	0.0%	+275.3%	0.042%
8/14/2024	Marshall Wace LLP	429,592	$2.94M	0.0%	N/A	0.277%
8/14/2024	Logos Global Management LP	5,150,000	$35.23M	2.8%	-11.4%	3.325%
8/14/2024	Paradigm Capital Management Inc. NY	300,000	$2.05M	0.1%	+114.3%	0.194%
8/14/2024	Tri Locum Partners LP	514,642	$3.52M	0.9%	N/A	0.332%
8/14/2024	Avoro Capital Advisors LLC	8,060,000	$55.13M	0.7%	+12.7%	5.204%
8/14/2024	HighVista Strategies LLC	61,859	$0.42M	0.2%	N/A	0.040%
8/14/2024	ProShare Advisors LLC	25,049	$0.17M	0.0%	-12.1%	0.016%
8/14/2024	Profund Advisors LLC	43,182	$0.30M	0.0%	+263.9%	0.028%
8/12/2024	Amalgamated Bank	5,384	$37K	0.0%	+37.9%	0.003%
8/5/2024	Arizona State Retirement System	28,151	$0.19M	0.0%	N/A	0.018%
8/5/2024	Victory Capital Management Inc.	17,403	$0.12M	0.0%	+36.9%	0.011%
8/3/2024	TD Asset Management Inc	112,800	$0.77M	0.0%	+40.3%	0.073%
8/1/2024	Rhumbline Advisers	211,301	$1.45M	0.0%	+39.1%	0.136%
7/31/2024	Aptus Capital Advisors LLC	262,810	$1.80M	0.0%	N/A	0.170%
7/30/2024	Atlas Capital Advisors LLC	5,000	$34K	0.0%	N/A	0.003%
7/29/2024	Principal Financial Group Inc.	26,364	$0.18M	0.0%	-5.4%	0.017%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	32,044	$0.22M	0.0%	+757.9%	0.021%
7/29/2024	Banco Santander S.A.	377,368	$2.58M	0.0%	+81.3%	0.244%
7/26/2024	Bank of New York Mellon Corp	495,635	$3.39M	0.0%	+49.6%	0.320%
7/16/2024	Deltec Asset Management LLC	2,590,265	$17.72M	3.4%	+9.6%	1.672%
7/12/2024	Rosalind Advisors Inc.	750,000	$5.13M	3.8%	N/A	0.484%
7/9/2024	Dudley & Shanley Inc.	16,200	$0.11M	0.0%	N/A	0.010%
5/29/2024	Opaleye Management Inc.	6,653,138	$60.54M	13.2%	+9.6%	4.295%
5/24/2024	Cetera Advisors LLC	723,490	$6.58M	0.1%	+1,455.0%	0.467%
5/24/2024	Cetera Investment Advisers	725,990	$6.61M	0.0%	+6.5%	0.469%
5/16/2024	Bayesian Capital Management LP	10,304	$94K	0.0%	N/A	0.007%
5/15/2024	Price T Rowe Associates Inc. MD	662,672	$6.03M	0.0%	+1,142.3%	0.428%
5/15/2024	Avoro Capital Advisors LLC	7,148,936	$65.06M	0.8%	N/A	4.615%
5/14/2024	EntryPoint Capital LLC	15,312	$0.14M	0.1%	N/A	0.010%
5/14/2024	American International Group Inc.	56,981	$0.52M	0.0%	+43.4%	0.037%
5/13/2024	Ameritas Investment Partners Inc.	11,531	$0.11M	0.0%	+39.4%	0.007%
5/10/2024	Vanguard Group Inc.	7,235,131	$65.84M	0.0%	+41.4%	4.676%
5/10/2024	Banco Santander S.A.	208,196	$1.90M	0.0%	-61.5%	0.135%
5/8/2024	ProShare Advisors LLC	28,498	$0.26M	0.0%	+55.7%	0.018%
5/7/2024	SG Americas Securities LLC	28,946	$0.26M	0.0%	+47.3%	0.019%
5/6/2024	Quantbot Technologies LP	46,500	$0.42M	0.0%	N/A	0.030%
5/3/2024	Essex Investment Management Co. LLC	376,200	$3.42M	0.7%	+1.6%	0.243%
5/1/2024	BNP Paribas Financial Markets	185,308	$1.69M	0.0%	+373.1%	0.120%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	53,456	$0.49M	0.0%	N/A	0.035%
4/29/2024	Principal Financial Group Inc.	27,880	$0.25M	0.0%	+27.0%	0.018%
4/29/2024	China Universal Asset Management Co. Ltd.	21,199	$0.19M	0.0%	+130.6%	0.014%
4/24/2024	Simplicity Wealth LLC	28,987	$0.26M	0.0%	N/A	0.019%
4/17/2024	Deltec Asset Management LLC	2,364,084	$21.51M	4.2%	-3.3%	1.591%
3/8/2024	Trust Co. of Vermont	6,000	$27K	0.0%	+20.0%	0.008%
2/26/2024	Virtu Financial LLC	62,066	$0.28M	0.0%	N/A	0.078%
2/15/2024	Opaleye Management Inc.	6,070,000	$27.07M	7.3%	-6.2%	7.643%
2/15/2024	Great Point Partners LLC	700,000	$3.12M	0.5%	N/A	0.881%
2/14/2024	Artia Global Partners LP	440,000	$1.96M	0.6%	N/A	0.554%
2/13/2024	Aristides Capital LLC	50,226	$0.22M	0.1%	N/A	0.063%
2/13/2024	Tower Research Capital LLC TRC	9,756	$44K	0.0%	+142.3%	0.012%
2/9/2024	Franklin Resources Inc.	4,500,159	$20.07M	0.0%	N/A	5.666%
2/8/2024	Essex Investment Management Co. LLC	370,372	$1.65M	0.3%	N/A	0.466%
2/7/2024	Ieq Capital LLC	30,129	$0.13M	0.0%	-64.4%	0.038%
2/5/2024	Victory Capital Management Inc.	10,135	$45K	0.0%	N/A	0.013%
1/29/2024	Simplicity Solutions LLC	44,987	$0.20M	0.0%	N/A	0.057%
1/24/2024	China Universal Asset Management Co. Ltd.	9,192	$41K	0.0%	+350.6%	0.012%
1/22/2024	Deltec Asset Management LLC	2,443,607	$10.90M	2.5%	+18.5%	3.077%
1/18/2024	Relyea Zuckerberg Hanson LLC	17,600	$78K	0.0%	N/A	0.022%

Data available starting January 2016

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $8.83

$8.41

$8.88

50 Day Range

MA: $9.90

$8.46

$11.47

52 Week Range

Now: $8.83

$2.14

$11.77

Volume

819,876 shs

Average Volume

947,681 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Who are the company insiders with the largest holdings of Ocular Therapeutix?: Ocular Therapeutix's top insider investors include:
Summer Road Llc (Major Shareholder)
Antony C Mattessich (CEO)
Sanjay Nayak (Insider)
Donald Notman (CFO)
Philip C Strassburger (General Counsel)
Rabia Gurses Ozden (Insider)
Christopher G White (Insider)
Learn More about top insider investors at Ocular Therapeutix.
Who are the major institutional investors of Ocular Therapeutix?: Ocular Therapeutix's top institutional investors include:
State Street Corp — 2.23%
Geode Capital Management LLC — 2.10%
Assenagon Asset Management S.A. — 1.81%
Deltec Asset Management LLC — 1.67%
Braidwell LP — 1.44%
Point72 Asset Management L.P. — 1.31%
Learn More about top institutional investors of Ocular Therapeutix stock.
Which major investors are selling Ocular Therapeutix stock?: In the previous quarter, OCUL stock was sold by these institutional investors:
Acuta Capital Partners LLC
Point72 Asset Management L.P.
State Street Corp
Banco Santander S.A.
Geode Capital Management LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
BNP Paribas Financial Markets
Principal Financial Group Inc.
Within the last year, company insiders that have sold Ocular Therapeutix company stock include:
Summer Road Llc (Major Shareholder)
Antony C Mattessich (CEO)
Sanjay Nayak (Insider)
Donald Notman (CFO)
Philip C Strassburger (General Counsel)
Learn More investors selling Ocular Therapeutix stock.
Which major investors are buying Ocular Therapeutix stock?: During the previous quarter, OCUL stock was acquired by institutional investors including:
Assenagon Asset Management S.A.
Charles Schwab Investment Management Inc.
Braidwell LP
Polar Asset Management Partners Inc.
FMR LLC
PFM Health Sciences LP
Knoll Capital Management LLC
Erste Asset Management GmbH
During the previous year, these company insiders have bought Ocular Therapeutix stock:
Summer Road Llc (Major Shareholder)
Antony C Mattessich (CEO)
Learn More investors buying Ocular Therapeutix stock.

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad